These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. BRAF inhibitor cessation prior to disease progression in metastatic melanoma: Long-term outcomes. Lee J; Ahmed T; Maurichi A; Di Guardo L; Stagno AM; Warburton L; Taylor AM; Livingstone E; Rehman S; Khattak A; Kahler KC; Vanella V; Atkinson V; Millward M; Schadendorf D; Johnson DB; Ascierto PA; Hauschild A; Lo SN; Long GV; Menzies AM; Carlino MS Eur J Cancer; 2023 Jan; 179():87-97. PubMed ID: 36509002 [TBL] [Abstract][Full Text] [Related]
23. Exploiting Allosteric Properties of RAF and MEK Inhibitors to Target Therapy-Resistant Tumors Driven by Oncogenic BRAF Signaling. Adamopoulos C; Ahmed TA; Tucker MR; Ung PMU; Xiao M; Karoulia Z; Amabile A; Wu X; Aaronson SA; Ang C; Rebecca VW; Brown BD; Schlessinger A; Herlyn M; Wang Q; Shaw DE; Poulikakos PI Cancer Discov; 2021 Jul; 11(7):1716-1735. PubMed ID: 33568355 [TBL] [Abstract][Full Text] [Related]
24. Clinical Development of BRAF plus MEK Inhibitor Combinations. Subbiah V; Baik C; Kirkwood JM Trends Cancer; 2020 Sep; 6(9):797-810. PubMed ID: 32540454 [TBL] [Abstract][Full Text] [Related]
25. Dabrafenib and trametinib, alone and in combination for BRAF-mutant metastatic melanoma. Menzies AM; Long GV Clin Cancer Res; 2014 Apr; 20(8):2035-43. PubMed ID: 24583796 [TBL] [Abstract][Full Text] [Related]
26. Checkpoint Inhibition in Addition to Dabrafenib/Trametinib for BRAF Hamidi S; Iyer PC; Dadu R; Gule-Monroe MK; Maniakas A; Zafereo ME; Wang JR; Busaidy NL; Cabanillas ME Thyroid; 2024 Mar; 34(3):336-346. PubMed ID: 38226606 [No Abstract] [Full Text] [Related]
27. Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial. Grob JJ; Amonkar MM; Karaszewska B; Schachter J; Dummer R; Mackiewicz A; Stroyakovskiy D; Drucis K; Grange F; Chiarion-Sileni V; Rutkowski P; Lichinitser M; Levchenko E; Wolter P; Hauschild A; Long GV; Nathan P; Ribas A; Flaherty K; Sun P; Legos JJ; McDowell DO; Mookerjee B; Schadendorf D; Robert C Lancet Oncol; 2015 Oct; 16(13):1389-98. PubMed ID: 26433819 [TBL] [Abstract][Full Text] [Related]
28. Systemic therapy for Asian patients with advanced BRAF V600-mutant melanoma in a real-world setting: A multi-center retrospective study in Japan (B-CHECK-RWD study). Namikawa K; Ito T; Yoshikawa S; Yoshino K; Kiniwa Y; Ohe S; Isei T; Takenouchi T; Kato H; Mizuhashi S; Fukushima S; Yamamoto Y; Inozume T; Fujisawa Y; Yamasaki O; Nakamura Y; Asai J; Maekawa T; Funakoshi T; Matsushita S; Nakano E; Oashi K; Kato J; Uhara H; Miyagawa T; Uchi H; Hatta N; Tsutsui K; Maeda T; Matsuya T; Yanagisawa H; Muto I; Okumura M; Ogata D; Yamazaki N Cancer Med; 2023 Sep; 12(17):17967-17980. PubMed ID: 37584204 [TBL] [Abstract][Full Text] [Related]
29. Clinical responses to vemurafenib in patients with metastatic papillary thyroid cancer harboring BRAF(V600E) mutation. Kim KB; Cabanillas ME; Lazar AJ; Williams MD; Sanders DL; Ilagan JL; Nolop K; Lee RJ; Sherman SI Thyroid; 2013 Oct; 23(10):1277-83. PubMed ID: 23489023 [TBL] [Abstract][Full Text] [Related]
30. BRAF inhibitor discontinuation and rechallenge in advanced melanoma patients with a complete initial treatment response. Desvignes C; Abi Rached H; Templier C; Drumez E; Lepesant P; Desmedt E; Mortier L Melanoma Res; 2017 Jun; 27(3):281-287. PubMed ID: 28240681 [TBL] [Abstract][Full Text] [Related]
31. An observational study of drug utilization and associated outcomes among adult patients diagnosed with BRAF-mutant advanced melanoma treated with first-line anti-PD-1 monotherapies or BRAF/MEK inhibitors in a community-based oncology setting. Cowey CL; Boyd M; Aguilar KM; Beeks A; Krepler C; Scherrer E Cancer Med; 2020 Nov; 9(21):7863-7878. PubMed ID: 32871054 [TBL] [Abstract][Full Text] [Related]
32. The concepts of rechallenge and retreatment in melanoma: A proposal for consensus definitions. Gebhardt C; Ascierto P; Atkinson V; Corrie P; Dummer R; Schadendorf D Eur J Cancer; 2020 Oct; 138():68-76. PubMed ID: 32861208 [TBL] [Abstract][Full Text] [Related]
34. Clinicopathologic features associated with efficacy and long-term survival in metastatic melanoma patients treated with BRAF or combined BRAF and MEK inhibitors. Menzies AM; Wilmott JS; Drummond M; Lo S; Lyle M; Chan MM; Thompson JF; Guminski A; Carlino MS; Scolyer RA; Kefford RF; Long GV Cancer; 2015 Nov; 121(21):3826-35. PubMed ID: 26218930 [TBL] [Abstract][Full Text] [Related]
35. The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma. Van Allen EM; Wagle N; Sucker A; Treacy DJ; Johannessen CM; Goetz EM; Place CS; Taylor-Weiner A; Whittaker S; Kryukov GV; Hodis E; Rosenberg M; McKenna A; Cibulskis K; Farlow D; Zimmer L; Hillen U; Gutzmer R; Goldinger SM; Ugurel S; Gogas HJ; Egberts F; Berking C; Trefzer U; Loquai C; Weide B; Hassel JC; Gabriel SB; Carter SL; Getz G; Garraway LA; Schadendorf D; Cancer Discov; 2014 Jan; 4(1):94-109. PubMed ID: 24265153 [TBL] [Abstract][Full Text] [Related]
36. Cautious addition of targeted therapy to PD-1 inhibitors after initial progression of BRAF mutant metastatic melanoma on checkpoint inhibitor therapy. Samlowski W; Adajar C BMC Cancer; 2021 Nov; 21(1):1187. PubMed ID: 34743688 [TBL] [Abstract][Full Text] [Related]
37. Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor. Kim KB; Kefford R; Pavlick AC; Infante JR; Ribas A; Sosman JA; Fecher LA; Millward M; McArthur GA; Hwu P; Gonzalez R; Ott PA; Long GV; Gardner OS; Ouellet D; Xu Y; DeMarini DJ; Le NT; Patel K; Lewis KD J Clin Oncol; 2013 Feb; 31(4):482-9. PubMed ID: 23248257 [TBL] [Abstract][Full Text] [Related]
38. Discovery of a novel pan-RAF inhibitor with potent anti-tumor activity in preclinical models of BRAF Hong SP; Ahn SK Life Sci; 2017 Aug; 183():37-44. PubMed ID: 28645859 [TBL] [Abstract][Full Text] [Related]
39. Next generation sequencing of exceptional responders with BRAF-mutant melanoma: implications for sensitivity and resistance. Wheler J; Yelensky R; Falchook G; Kim KB; Hwu P; Tsimberidou AM; Stephens PJ; Hong D; Cronin MT; Kurzrock R BMC Cancer; 2015 Feb; 15():61. PubMed ID: 25886620 [TBL] [Abstract][Full Text] [Related]